NCT05493111View on ClinicalTrials.gov

A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512

PHASE3CompletedINTERVENTIONAL
Enrollment

275

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

February 28, 2024

Study Completion Date

February 28, 2024

Conditions
Dry Eye Disease
Interventions
DRUG

0.003% AR-15512 ophthalmic solution

Active ingredients administered via topical ocular instillation

DRUG

AR-15512 vehicle ophthalmic solution

Inactive ingredients administered via topical ocular instillation

Trial Locations (10)

11030

SightMD, Manhasset

24502

Piedmont Eye Center, Lynchburg

37803

University Eye Specialists, Maryville

85225

Arizona Eye Center, Chandler

85351

Arizona Eye Institute, Sun City

90048

Macy Eye Center, Los Angeles

91204

Global Research Management, Glendale

91325

Shultz Vision, Northridge

92663

Eye Research Foundation, Newport Beach

98119

Periman Eye Institute, Seattle

Sponsors
All Listed Sponsors
lead

Aerie Pharmaceuticals

INDUSTRY

NCT05493111 - A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512 | Biotech Hunter | Biotech Hunter